AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-30. (canceled).

1 ~~31.~~ (previously presented) An isolated monoclonal antibody MJ-170 produced by hybridoma cell line MJ-170 on deposit with the American Type Culture Collection (ATCC) as accession number PTA-5286.

2 ~~32.~~ (previously presented) An isolated monoclonal antibody MJ-171 produced by hybridoma cell line MJ-171 on deposit with the ATCC as accession number PTA-5287.

3 ~~33.~~ (previously presented) An isolated monoclonal antibody MJ-172 produced by hybridoma cell line MJ-172 on deposit with the ATCC as accession number PTA-5288.

4 ~~34.~~ (previously presented) An isolated monoclonal antibody MJ-173 produced by hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.

5 ~~35.~~ (previously presented) A hybridoma cell line MJ-170 on deposit with the ATCC as accession number PTA-5286.

6 ~~36.~~ (previously presented) A hybridoma cell line MJ-171 on deposit with the ATCC as accession number PTA-5287.

7 ~~37.~~ (previously presented) A hybridoma cell line MJ-172 on deposit with the ATCC as accession number PTA-5288.

8 ~~38.~~ (previously presented) A hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.

39. (canceled).

9 ~~40.~~ (previously presented) An antibody of claim ~~31~~ 1, ~~32~~ 2, ~~33~~ 3 or ~~34~~ 4, wherein said antibody is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.

10 ~~41.~~ (previously presented) The antibody of claim ~~40~~ 9, wherein said cytotoxic agent is a small drug molecule.

11 ~~42.~~ (previously presented) The antibody of claim ~~40~~ 9, wherein said cytotoxic agent is a maytansinoid, a taxoid, or a CC-1065 analog.

12 ~~43.~~ (original) A composition comprising an antibody of claim ~~31~~ 1, ~~32~~ 2, ~~33~~ 3 or ~~34~~ 4 and a pharmaceutically acceptable carrier.

13 ~~44.~~ (previously presented) A composition comprising the antibody of claim ~~40~~ 9 and a pharmaceutically acceptable carrier.

14 ~~45.~~ (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim ~~43~~ 12.

15 ~~46.~~ (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim ~~44~~ 13.

47-48. (canceled).

16 ~~49.~~ (withdrawn) The method of claim ~~45~~ 14, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

17 ~~50.~~ (withdrawn) The method of claim ~~46~~ 15, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

18 ~~51.~~ (withdrawn) The method of claim ~~45~~ 14, wherein said cancer is ovarian cancer or breast cancer.

19 ~~52.~~ (withdrawn) The method of claim ~~46~~ 15, wherein said cancer is ovarian cancer or breast cancer.

20 ~~53.~~ (previously presented) An isolated antibody that specifically binds to a Muc1 peptide selected from the group consisting of:

a) QLTLAFREGTINVHDVETQFN (SEQ ID NO:8);

b) QYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);

c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and

d) VPFPFSAQSGAGVPGWGIA (SEQ ID NO:12).

21 ~~54.~~ (previously presented) An isolated antibody that specifically binds to a Muc16 peptide selected from the group consisting of:

a) SSVLVDGYSPNRNEPLTGNS (SEQ ID NO:14);

b) TNYQRNKRNIEDALNQLFRN (SEQ ID NO:15);

c) FRNSSIKSYFSDCQVSTFRSV (SEQ ID NO:16);

d) SVPNRHHTGVDSLCNFSPLARRV (SEQ ID NO:17); and

e) DRVAIYEEFLRMTRNGTQLQNFTLDRSS (SEQ ID NO:18).

22 ~~55.~~ (currently amended) The antibody of claim ~~53~~ 20 or ~~54~~ 21, wherein said antibody is selected from the group consisting of a monoclonal antibody, a recombinant antibody, an antigen-binding ~~a~~ fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage.

23 ~~56.~~ (previously presented) The antibody of claim ~~53~~ 20 or ~~54~~ 21, wherein said antibody is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.

24 ~~57.~~ (previously presented) The antibody of claim ~~56~~ 23, wherein said cytotoxic agent is a small drug molecule.

25 ~~58.~~ (previously presented) The antibody of claim ~~56~~ 23, wherein said cytotoxic agent is a maytansinoid, taxoid, or CC-1065 analog.

26 ~~59.~~ (previously presented) A composition comprising the antibody of claim ~~53~~ 20 or ~~54~~ 21 and a pharmaceutically acceptable carrier.

27 ~~60.~~ (previously presented) A composition comprising the antibody of claim ~~56~~ 23 and a pharmaceutically acceptable carrier.

28 ~~61.~~ (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim ~~59~~ 26.

29 ~~62.~~ (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim ~~60~~ 27.

30 ~~63.~~ (withdrawn) The method of claim ~~61~~ 28, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

31 ~~64.~~ (withdrawn) The method of claim ~~62~~ 29, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

32 ~~65~~. (withdrawn) The method of claim ~~61~~ 28 or ~~62~~ 29, wherein said cancer is ovarian cancer or breast cancer.

33 ~~66~~. (withdrawn) A method of screening a subject for cancer, comprising:

(a) measuring the amount of Muc1 in a biological sample obtained from a subject using the antibody of claim ~~53~~ 20; and

(b) comparing the amount of Muc1 measured in (a) to the amount of Muc1 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.

34 ~~67~~. (withdrawn) A method of screening a subject for cancer, comprising:

(a) measuring the amount of Muc16 in a biological sample obtained from a subject using the antibody of claim ~~54~~ 21; and

(b) comparing the amount of Muc16 measured in (a) to the amount of Muc16 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.

35 ~~68~~. (withdrawn) The method of claim ~~66~~ 33 or ~~67~~ 34, wherein said cancer is ovarian cancer or breast cancer.

69-70. (canceled).

36 ~~71~~. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC1 peptide selected from the group consisting of:

a) QLTLAFREGTINVHDVETQFN (SEQ ID NO:8);

b) QYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);

c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and

d) VPFPFSAQSGAGVPGWGIA (SEQ ID NO:12).

37 ~~72~~. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC16 peptide selected from the group consisting of:

a) SSVLVDGYSPNRNEPLTGNS (SEQ ID NO:14);

b) TNYQRNKRNIEDALNQLFRN (SEQ ID NO:15);

c) FRNSSIKSYFSDCQVSTFRSV (SEQ ID NO:16);

d) SVPNRHHTGVDSLCNFSPLARRV (SEQ ID NO:17); and

e) DRVAIYEEFLRMTRNGTQLQNFTLDRSS (SEQ ID NO:18).